Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,237 total articles
Alexandria Real Estate Equities (ARE) offers an attractive risk-reward today: a recurring quarterly payout that equates to a 5.9% yield at current prices, a price-to-book near 0.53 that implies roughly a 50% discount to tangible book, and an enterprise valuation that feels stretched only because of temporary operating headwinds. This trade idea lay…
Grail's failed NHS Galleri readout on 08/01/2026 triggered headline selling across genomic names. Illumina (ILMN) has been swept up, but the company still generates strong free cash flow ($931M), carries manageable leverage (debt/equity ~0.7), and trades near $192.93 with a market cap of about $29.13B. This trade idea lays out an actionable long: e…
CytomX (CTMX) is a clinical-stage oncology biotech advancing varsetatug masetecan (Varseta-M) with upside driven by clinical progress and partnership milestones. A $250M equity raise in March 2026 and a June expansion of the Regeneron collaboration meaningfully reduce near-term dilution risk and extend runway, creating a favorable risk-reward for a…
Greggs is a resilient, cash-generative UK bakery chain trading at a valuation that looks fair but not demanding. A disciplined long entry here balances upside from execution and new product momentum against macro and commodity risks. Trade plan: enter at $25.00, target $30.00, stop $21.00 — horizon: long term (180 trading days).
Cognex (CGNX) is a profitable, cash-generative machine vision leader that the market appears to be discounting relative to its exposure to AI-driven data center and semiconductor supply chains. Strong margins, zero financial debt, and $268M in free cash flow underpin a long-term trade with a favorable risk-reward.
Watts Water Technologies is benefiting from AI-driven data-center infrastructure demand and a recovering Europe after a tough 2025. With a $14.2B market cap, clean balance sheet and strong free cash flow, the stock looks set to re-rate. This is a tactical long idea with a mid-term (45 trading days) horizon: enter on strength at $386.37, stop at $36…
908 Devices makes small, mission-critical mass spectrometers used by customs, food labs, and biotech clients. Recent contract wins and steady top-line growth (Q2 2025 revenue $13.0M, +14% YoY) alongside a manageable enterprise value (~$346M) support a tactical long. Expect near-term volatility; plan for a defined entry, stop and target over a 180 t…
Excelerate Energy is executing an asset-recycling strategy that converts merchant LNG exposure into fee-like, contracted regas capacity via FSRUs and terminal stakes. At roughly $36/share the stock trades at modest multiples (EV/EBITDA ~3.8, P/S 0.75) while recent deals and EBITDA beats show the model can scale. This trade captures a path to higher…
Descartes reported a clean Q1 with 15% revenue growth and expanding operating margin; combined with $377M cash and targeted AI acquisitions, the setup favors a long trade. Valuation is rich but justified by recurring SaaS revenue, network effects and steady free cash flow. Entry $77.00, stop $70.00, target $95.00 over a long-term (180 trading days)…
Sphere Entertainment (SPHR) is trading near its 52-week high as the company converts a unique venue into a content and advertising platform. Strong cash flow, modest leverage and visible revenue ramps from ticketing, Exosphere advertising and licensing justify a constructive trade. This idea is actionable with a clear entry at $173.85, a stop at $1…
Astera Labs is trading on momentum after AWS' AI strength and the company’s own accelerating revenue and cash generation. With profitable margins, a debt-free balance sheet and improving technicals, ALAB offers an asymmetric risk/reward for a disciplined swing trade. Entry $332.63, stop $305.00, target $420.00 — mid-term horizon (45 trading days).
CECO Environmental (CECO) has delivered on the two biggest near-term items investors were watching: a strengthened orders outlook and a strategic merger with Thermon that adds scale and cross-selling opportunity. Fundamentals remain mixed — high valuation and modest free cash flow — but the combination, order growth target (> $1.5B), and improving …
Reports that Riot Platforms may be linked to a $9.1 billion Anthropic deal are unconfirmed but consequential. Given Riot's $7.9B market cap, heavy hash-rate growth, and under-levered balance sheet, a confirmed AI partnership or large contract would materially change valuation expectations. This trade idea outlines a long entry at $21.07, a conserva…
Damora (DMRA) is trading at $31.27 with a market cap near $2.0B and a cash-rich balance sheet. Competition that validates galectin-3/LOXL2 biology de-risks the thesis while internal programs and corporate actions create multiple paths to upside. This is a medium-risk long trade: enter near $31.27, stop at $27.00, target $38.00 over a position horiz…
AMAL has run up to the low $50s, trading at a P/E in the low teens and a market cap near $1.52B, but consensus 12-month analyst targets sit around $30. A technical stall at the 52-week high and declining short-interest trajectory set up a trade that profits if the name re-rates toward analyst levels. We lay out an entry, stop, targets and the key c…
Butterfly Network has moved from gadget to platform: a $2.95B market cap, strong balance-sheet ratios, and accelerating adoption of AI-enabled point-of-care imaging support a long trade. Entry at $9.22 with a $13.00 target and $7.50 stop, held over a 120 trading-day horizon, balances upside from software/recurring revenue with the valuation and ins…
Eli Lilly’s next-generation obesity candidate retatrutide and a blistering Q2 performance force a reassessment. The market has priced growth into a premium multiple, but retatrutide’s efficacy (28.3% mean weight loss in Phase 3) plus robust cash generation and raised guidance make a compelling asymmetric long. This trade idea lays out an entry at $…
eToro's trading activity has cooled — smaller check sizes and weaker crypto flows — yet the stock trades at a modest multiple with profitable operations, a $150M buyback in the background, and acquisition-driven crypto capability expansion. Technicals are deeply oversold, creating an asymmetric mid-term trade if you size risk carefully.
Woodward's mix of aerospace controls and industrial flow/motion products is getting a tailwind from rising commercial services, LEAP engine MRO partnerships, and broad industrial demand across power generation and transportation. Recent results and guidance upgrades justify a bullish tactical position. Entry at $362, stop at $330, target $420 with …
Western Digital sold off on what looks like profit-taking after a strong quarter and bullish guidance. With AI-driven data-center demand, healthy free cash flow, modest leverage, and an attractive entry after the pullback, I’m upgrading to a buy for a mid-term swing trade with clear entry, stop and target levels.
Palantir posted a Q2 that rewrites the AI playbook for large-enterprise software: 93% revenue growth, U.S. commercial up 149%, and a 55% net margin. That operating strength and raised guidance justify a long-term buy thesis, but the stock already prices in years of rapid execution. I outline a disciplined entry at $165.00, a $145 stop, and a $220 t…
Carriage Services (CSV) looks like an asymmetric opportunity today. The stock is trading at $33.96, under pressure from thin volume and a debt load that will likely require refinancing activity in the coming quarters. Fundamentals remain cash-generative - free cash flow of $37.4M and an EV/EBITDA of 8.6 - which gives management room to negotiate te…
Lumentum (LITE) trades at nosebleed multiples - PE ~145, EV/EBITDA ~103, and price-to-free-cash-flow ~560x - pricing flawless execution and sustained hypergrowth. Recent earnings and guidance (market reaction) suggest demand variability and margin sensitivity; that combination creates a high-reward trade to fade optimism. Short at $945.41, stop $1,…
Nutex Health is attractively valued given a $1.27B market cap, $269M in free cash flow and low EV/EBITDA of 4.2x. Recent one-time arbitration true-ups and improving operating metrics set up margin expansion and a re-rating. We upgrade to Strong Buy with an actionable trade plan: entry $170.00, stop $150.00, target $225.00 (long term, 180 trading da…
Netflix is positioned to convert structural subscriber upside and improve margins through its ad-tier rollout, password-sharing monetization, and content spending normalization. We argue the market is underestimating 2027 earnings power. Trade plan: enter $520.00, stop $460.00, target $650.00 over a 180 trading-day horizon.
